VieCure Announces Appointment of Howard L. McLeod, PharmD, to the Position of Senior Research Advisor in Precision Medicine

VieCure (Greenwood Village, CO) announced the appointment of Dr. Howard McLeod, to the position of Senior Research Advisor in Precision Medicine.  McLeod will also join the VieCure Clinical Advisory Board.   He is well known to the Precision Medicine community given his leadership responsibilities for the Department of Individualized Cancer Management at the H. Lee Moffitt Cancer Center in Tampa Bay, Florida.

McLeod is an endowed Research Chair in the State of Florida and a Professor at the University of South Florida.  He is also a 1000 Talent Scholar in China and has served on the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council.  He is vice chair for Pharmacogenomics for NCI ALLIANCE clinical trials group, overseeing the largest oncology pharmacogenomics portfolio in the world.  As an active entrepreneur, he serves on the Board of Directors, Scientific Advisory Board, and as a domain expert consultant to publicly traded and privately held companies.  He has also founded both for-profit and non-profit companies in the USA and China and has published over 500 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance individualized medicine.

In his role with VieCure, Dr. McLeod will assist in translating research and clinical advances in precision medicine in oncology.  He will help to drive the VieCure technology roadmap and will function as an active ambassador of the Company and the VCurePrecision™ AI platform at national and international research and clinical symposia.

Gerry Hogue, President and CEO of VieCure, highlighted Dr. McLeod’s contributions to precision medicine in oncology and the opportunity to work with Dr. McLeod to generate codified clinical rules that put world-leading cancer knowledge at the fingertips of patients and oncologists. “We are extremely pleased to have Dr. Howard McLeod join VieCure’s Precision Medicine Advisory Board.  His depth of knowledge and leadership in genomic-guided therapies, and his commitment to improving point-of-care decision-making and patient outcomes is widely known and respected.”

Dr. McLeod shared his enthusiasm with joining the advisory board: “There are practical challenges for oncologists to deliver precision medicine, from the high pace of new research to the lack of access to practical tools to turn the advances into treatment to help their patients.  I’m very excited by the opportunity to provide VieCure advice as it advances its platform to address these concerns by providing curated and codified world-leading guidance to support clinical decisions in standard of care and genomic-guided treatments.”

About VieCure

We codify the world’s premier cancer guidance from clinical research centers around the world into a technology platform that considers each patient’s unique needs and supports the care team, patient and their family through diagnosis, treatment and follow-up. VieCure is headquartered in Greenwood Village, Colorado.

Topics: